Kara Elam,  —

When a progressively debilitating disease like multiple sclerosis (MS) causes a patient to feel physically “wiped out” after a simple daily activity, such as a shower, it is of utmost importance for these individuals and the people in their support system to understand how they can maintain independence for…

The Americas Committee for the Treatment and Research in Multiple Sclerosis, otherwise known as ACTRIMS, says its third annual ACTRIMS Forum will take place Feb. 1-3, 2018, at the Hilton San Diego Bayfront in San Diego, California. These forums bolster the ACTRIMS mission, which is to foster the careers of young researchers interested in MS by promoting mentor relationships with senior scientists, and giving promising investigators a chance to present their early research findings. ACTRIMS 2017 was a record-breaking year with over 800 people attending. Organizers say 1,000 people will attend this year's conference. The 2018 forum's theme is “Therapeutic Targets in MS: The Frontier and the Future of Disease Modifying Therapy.” ACTRIMS 2018 also features continuing medical education credits for attendees, as well as participation grants for applicable young investigators.

Multiple sclerosis (MS) patients who used the RebiSmart (Merck Serono) device to inject themselves with interferon beta-1a (INF β-1a) did an excellent job of sticking to their treatment timetable without skipping treatments, according to a study. They also had a lower annual disease relapse rate and more relapse-free periods,…

Researchers from Oryzon will present efficacy data on the company’s oral epigenetic drug ORY-2001, a potential treatment for multiple sclerosis (MS), at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress taking place this week in London. The poster presentation, “LSD1 inhibition, a potential epigenetic therapeutic approach for…

Biogen, a global biotechnology company with over 30 years of clinical excellence in Multiple Sclerosis (MS) research, has recently announced the launch of Reimagine MySelf, a blog dedicated to helping women navigate their daily lives while also dealing with the complications that come with a diagnosis of relapsing…

This week, Belgian-based biopharmaceutical company Ablynx announced they have entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate the use of Nanobodies as part of a targeted therapeutic strategy for multiple sclerosis (MS).  The research will utilize Genzyme’s early-stage MS research programs involving neuroprotection…

This week the Consortium of Multiple Sclerosis Centers (CMSC) in collaboration with The France Foundation, a provider of continuing medical education have launched a new educational program focused on the important issues that affect women with multiple sclerosis (MS), entitled, “Strategies to Improve…

 A study published by a team of investigators at the University of Tokyo’s Institute of Medical Science and Osaka University’s Graduate School of Engineering presented new evidence demonstrating how Toll-like receptor 9 (TLR9) binds to pathogenic DNA, turning on the functions of the innate immune…